TY - JOUR
T1 - A chemical modulator of p53 transactivation that acts as a radioprotective agonist
AU - Morita, Akinori
AU - Takahashi, Ippei
AU - Sasatani, Megumi
AU - Aoki, Shin
AU - Wang, Bing
AU - Ariyasu, Shinya
AU - Tanaka, Kaoru
AU - Yamaguchi, Tetsuji
AU - Sawa, Akiko
AU - Nishi, Yurie
AU - Teraoka, Tatsuro
AU - Ujita, Shohei
AU - Kawate, Yosuke
AU - Yanagawa, Chihiro
AU - Tanimoto, Keiji
AU - Enomoto, Atsushi
AU - Nenoi, Mitsuru
AU - Kamiya, Kenji
AU - Nagata, Yasushi
AU - Hosoi, Yoshio
AU - Inaba, Toshiya
N1 - Funding Information:
This study was supported by KAKENHI (24689050 and 16K10396) from the Japan Society for the Promotion of Science (to A. Morita) and partly supported by the Program of the network-type joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University.
Publisher Copyright:
© 2017 AACR.
PY - 2018/2
Y1 - 2018/2
N2 - Inhibiting p53-dependent apoptosis by inhibitors of p53 is an effective strategy for preventing radiation-induced damage in hematopoietic lineages, while p53 and p21 also play radioprotective roles in the gastrointestinal epithelium. We previously identified some zinc(II) chelators, including 8-quinolinol derivatives, that suppress apoptosis in attempts to discover compounds that target the zinc-binding site in p53. We found that 5-chloro-8-quinolinol (5CHQ) has a unique p53-modulating activity that shifts its transactivation from proapoptotic to protective responses, including enhancing p21 induction and suppressing PUMA induction. This p53-modulating activity also influenced p53 and p53-target gene expression in unirradiated cells without inducing DNA damage. The specificity of 5CHQ for p53 and p21 was demonstrated by silencing the expression of each protein. These effects seem to be attributable to the sequence-specific alteration of p53 DNA-binding, as evaluated by chromatin immunoprecipitation and electrophoretic mobility shift assays. In addition, 5-chloro-8-methoxyquinoline itself had no antiapoptotic activity, indicating that the hydroxyl group at the 8-position is required for its antiapoptotic activity. We applied this remarkable agonistic activity to protecting the hematopoietic and gastrointestinal system in mouse irradiation models. The dose reduction factors of 5CHQ in total-body and abdominally irradiated mice were about 1.2 and 1.3, respectively. 5CHQ effectively protected mouse epithelial stem cells from a lethal dose of abdominal irradiation. Furthermore, the specificity of 5CHQ for p53 in reducing the lethality induced by abdominal irradiation was revealed in Trp53-KO mice. These results indicate that the pharmacologic upregulation of radioprotective p53 target genes is an effective strategy for addressing the gastrointestinal syndrome.
AB - Inhibiting p53-dependent apoptosis by inhibitors of p53 is an effective strategy for preventing radiation-induced damage in hematopoietic lineages, while p53 and p21 also play radioprotective roles in the gastrointestinal epithelium. We previously identified some zinc(II) chelators, including 8-quinolinol derivatives, that suppress apoptosis in attempts to discover compounds that target the zinc-binding site in p53. We found that 5-chloro-8-quinolinol (5CHQ) has a unique p53-modulating activity that shifts its transactivation from proapoptotic to protective responses, including enhancing p21 induction and suppressing PUMA induction. This p53-modulating activity also influenced p53 and p53-target gene expression in unirradiated cells without inducing DNA damage. The specificity of 5CHQ for p53 and p21 was demonstrated by silencing the expression of each protein. These effects seem to be attributable to the sequence-specific alteration of p53 DNA-binding, as evaluated by chromatin immunoprecipitation and electrophoretic mobility shift assays. In addition, 5-chloro-8-methoxyquinoline itself had no antiapoptotic activity, indicating that the hydroxyl group at the 8-position is required for its antiapoptotic activity. We applied this remarkable agonistic activity to protecting the hematopoietic and gastrointestinal system in mouse irradiation models. The dose reduction factors of 5CHQ in total-body and abdominally irradiated mice were about 1.2 and 1.3, respectively. 5CHQ effectively protected mouse epithelial stem cells from a lethal dose of abdominal irradiation. Furthermore, the specificity of 5CHQ for p53 in reducing the lethality induced by abdominal irradiation was revealed in Trp53-KO mice. These results indicate that the pharmacologic upregulation of radioprotective p53 target genes is an effective strategy for addressing the gastrointestinal syndrome.
UR - http://www.scopus.com/inward/record.url?scp=85041474121&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041474121&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-16-0554
DO - 10.1158/1535-7163.MCT-16-0554
M3 - Article
C2 - 28939557
AN - SCOPUS:85041474121
SN - 1535-7163
VL - 17
SP - 432
EP - 442
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
IS - 2
ER -